Adjuvant Activity on Human Cells In Vitro

  • Dominique De WitEmail author
  • Michel Goldman
Part of the Methods in Molecular Biology book series (MIMB, volume 626)


Efficient vaccines against intracellular microbes or tumors will be based on innovative adjuvants able to induce efficient activation of dendritic cells. Indeed, natural or synthetic products activating Toll-like receptors (TLR) on dendritic cells (DCs) are currently in development for this purpose. Herein, we describe in vitro assays on human cells which might be useful for the preclinical screening and assessment of potential DC activators.

Key words

Dendritic cells TLR ligands whole blood cells HEK 293 cell line adjuvants 


  1. 1.
    Steinman, R. M. (2003) Some interfaces of dendritic cell biology. Apmis 111, 675–697.PubMedCrossRefGoogle Scholar
  2. 2.
    Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., Narasimhan, B. (2008) Vaccine adjuvants: current challenges and future approaches review. J Pharm Sci 10, 1–39.Google Scholar
  3. 3.
    De Gregorio, E., Tritto, E., Rappuoli, R. (2008) Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38, 2068–2071.PubMedCrossRefGoogle Scholar
  4. 4.
    Li, H., Nookala, S., Re, F. (2007) Aluminium hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-8 release. J Immunol 178, 5271–5276.PubMedGoogle Scholar
  5. 5.
    Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., Flavell, R. A. (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122–1126.PubMedCrossRefGoogle Scholar
  6. 6.
    McKee, A. S., Munks, M. W., Marrack, P. (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27, 687–690.PubMedCrossRefGoogle Scholar
  7. 7.
    Fajardo-Moser, M., Berzel, S., Moll, H. (2008) Mechanisms of dendritic cell-based vaccination against infection. Int J Med Microbiol 298, 11–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Kanzler, H., Barrat, F. J., Hessel, E. M., Coffman, R. L. (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13, 552–559.PubMedCrossRefGoogle Scholar
  9. 9.
    van Duin, D., Medzhitov, R., Shaw, A. C. (2006) Triggering TLR signaling in vaccination. TRENDS Immunol 27, 49–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Kawai, T., Akira, S. (2006) TLR signaling review. Cell Death Differ 13, 816–825.PubMedCrossRefGoogle Scholar
  11. 11.
    McKenna, K., Beignon, A. S., Bhardwaj, N. (2005) Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79, 17–27.PubMedCrossRefGoogle Scholar
  12. 12.
    Pasare, C., Medzhitov, R. (2004) Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 6, 1382–1387.PubMedCrossRefGoogle Scholar
  13. 13.
    Goriely, S., Molle, C., Nguyen, M., Albarani, V., Ouled, H. N., Lin, R., De Wit, D., Flamand, V., Willems, F., Goldman, M. (2006) Interferon regulatory factor 3 is involved in toll like receptor (TLR)4- and TLR3-induced IL-12p35 gene activation. Blood 107, 1078–1084.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhu, Q., Egelston, C., Vivekanandhan, A., Uematsu, S., Akira, S., Klinman, D. M., Beyakov, I. M., Berzofsky, J. A. (2008) Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. PNAS 105, 16260–16265.PubMedCrossRefGoogle Scholar
  15. 15.
    Garçon, N., Chomez, P., Van Mechelen, M. (2007) GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6, 723–739.PubMedCrossRefGoogle Scholar
  16. 16.
    Giannini, S. L., Hanon, E., Moris, P., Van Mechelen, M., Morel, S., Dessy, F., Fourneau, M. A., Colau, B., Suzich, J., Losonksy, G., Martin, M.-T., Dublin, G., Wettendorff, M. A. (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combinaison (ASO4) compared to aluminium salt only. Vaccine 24, 5937–5949.PubMedCrossRefGoogle Scholar
  17. 17.
    Stövert, A. G., Da Silva Correias, J., Evans, J. T., Cluff, C. W., Elliott, M. W., Jeffrey, E. W., Johnson, D. A., Lacy, M. J., Baldridge, J. R., Probst, P., Ulevitch, R. J., Persing, D. H., Hershberg, R. M. (2004) Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J Biol Chem Vol 279, 4440–4449.CrossRefGoogle Scholar
  18. 18.
    Cluff, C. W., Baldridge, J. R., Stöver, A. G., Evans, J. T., Johnson, D. A., Lacy, M. J., Clawson, V. G., Yorgensen, V. M., Johnson, C. L., Livesay, M. T., Hershberg, R. M., Persing, D. H. (2005) Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 73, 3044–3052.PubMedCrossRefGoogle Scholar
  19. 19.
    Romani, N. S., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacker, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., Schuler, G. (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180, 83–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., Lanzavecchia, A. (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6, 769–776.PubMedCrossRefGoogle Scholar
  21. 21.
    Kapsenberg, M. L. (2003) Dendritic-cell control of pathogen-driven T-cell polarisation. Nat Rev Immunol 3, 984–993.PubMedCrossRefGoogle Scholar
  22. 22.
    Ida, J. A., Shrestha, N., Desai, S., Pahwa, S., Hanekom, W. A., Haslett, P. A. (2006) A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J Immunol Methods 310, 86–99.PubMedCrossRefGoogle Scholar
  23. 23.
    De Wit, D., Tonon, S., Olislagers, V., Goriely, S., Boutriaux, M., Goldman, M., Willems, F. (2003) Impaired responses to Toll-like receptor 4 and Toll-like receptor 3 ligands in human cord blood. J Autoimmun 21, 277–281.PubMedCrossRefGoogle Scholar
  24. 24.
    Stordeur, P., Zhou, L., Byl, B., Brohet, F., Burny, W., de Groote, D., van der Poll, T., Goldman, M. (2003) Immune monitoring in whole blood using real time PCR. J Immunol Methods 276, 69–76.PubMedCrossRefGoogle Scholar
  25. 25.
    Danis, B., George, T. C., Goriely, S., Dutta, B., Renneson, J., Gatto, L., Fitzgerald-Bocarsly, P., Marchant, A., Goldman, M., Willems, F., De Wit, D. (2008) Interferon regulatory factor7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur J Immunol 38, 507–517.PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson, J., Albarani, V., Nguyen, M., Goldman, M., Willems, F., Aksoy, E. (2007) Protein kinase Cα is involved in interferon regulatory factor 3 and type I interferon-β synthesis. J Biol Chem 282, 15022–15032.PubMedCrossRefGoogle Scholar
  27. 27.
    Medvedev, A. E., Lentschat, A., Whal, L. M., Golenbock, D. T., Vogel, S. N. (2002) Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 169, 5209–5216.PubMedGoogle Scholar
  28. 28.
    Aksoy, E., Albarani, V., Nguyen, M., Laes, J. F., Ruelle, J. L., De Wit, D., Willems, F., Goldman, M., Goriely, S. (2007) Interferon regulatory factor-3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells. Blood 109, 2887–2893.PubMedGoogle Scholar
  29. 29.
    Vollmer, J., Weeratna, R., Payette, P., Jurk, M., Schetter, C., Laucht, M., Wader, T., Tluk, S., Liu, M., Davis, H. L., Krieg, A. M. (2004) Characterization of three CpG oligodeoxynucleotides classes with distinct immunostimulatory activities. Eur J Immunol 34, 251–262.PubMedCrossRefGoogle Scholar
  30. 30.
    Latz, E., Visintin, A., Lien, E., Fitzgerald, K. A., Monks, B. G., Kurt-Jones, E. A., Golenbock, D. T. (2002) Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 277, 47834–47843.PubMedCrossRefGoogle Scholar
  31. 31.
    Jiang, Z., Geogel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., Huber, M., Kalis, C., Keck, S., Galanos, C., Freudenberg, M., Beutler, B. (2005) CD14 is required for MyD88-independent LPS signalling. Nat Immunol 6, 565–570.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Institut d’Immunologie Médicale, Université Libre de BruxellesCharleroiBelgium

Personalised recommendations